EGFR and colonic neoplasm: We, and others, have previously shown that colon tumours that acquire resistance to anti-EGFR drugs cetuximab and gefitinib overexpress Akt and VEGF, which act as the escape pathways to overcome the EGFR blockade (Viloria-Petit et al, 2001; Ciardiello et al, 2004; Bianco et al, 2005).